Home FDA rejects Amarin appeal on Vascepa trial design, shares slump
 

Keywords :   


FDA rejects Amarin appeal on Vascepa trial design, shares slump

2014-01-22 11:50:08| Biotech - Topix.net

Amarin Corp Plc's shares fell more than 26 percent after U.S. health regulators rejected a preset testing process that was critical to the company seeking broader use of its blood fat-lowering drug.

Tags: design trial shares appeal

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
05.10Weekly Recap: BASF, Beckers, Allnex, Sherwin-Williams Top This Weeks Stories
05.10Hurricane Kirk Graphics
05.10Hurricane Kirk Forecast Discussion Number 24
05.10Hurricane Kirk Wind Speed Probabilities Number 24
05.10Hurricane Kirk Forecast Advisory Number 24
05.10Hurricane Kirk Public Advisory Number 24
05.10Summary for Hurricane Kirk (AT2/AL122024)
05.10Hurricane Leslie Graphics
More »